Gerald Cagle, Ph.D., Board Chairman

Gerald Cagle, Ph.D. has served as a member of the Eyevensys Board since 2017 and was appointed Board Chair in January, 2020. He worked in Alcon's Research & Development for approximately 32 years and was the company's Senior Vice President and Chief Scientific Officer from 1996 to 2009 when he retired. From 2009 until 2013, he held the position of Chief Operating Officer at Cognoptix, a company focused on the diagnosis of Alzheimer's disease. Dr. Cagle currently serves on the board of directors of Aerie Pharmaceuticals, GrayBug Vision, Nacuity Pharmaceuticals, Inc. and AB2 Bio Ltd. Dr. Cagle received his B.S. from Wayland College, earned both his M.S. and Ph.D. from the University of North Texas and completed the Program for Management Development at Harvard Business School.

Dr Francine Behar-Cohen, MD, Founder of Eyevensys

Francine founded Eyevensys in December 2008. From 2013 to 2016, she was the Chief Medical Officer of the Gonin Lausanne Ophthalmology Hospital in Switzerland. She is Professor of Ophthalmology at Paris Descartes University (France), Head of the Department of Ophthalmology of Hôtel-Dieu – University of Paris Descartes Hospital, and Director of the “Physiopathology of Ocular Diseases” lab at the Cordeliers INSERM Centre. She has authored over 164 publications since 1999. Very entrepreneurially oriented, Francine also founded Eyegate Pharma in 1997.

Prof.Dr. Johannes Zanzinger

Johannes is an Investment Manager at the Boehringer Ingelheim Venture Fund (BIVF) since May 2019, and serves as a Director at AgomAb Therapeutics (Gent), Eyevensys (Paris), and Heparegenix (Tübingen). Johannes gained R&D and management experience across multiple disease areas in academia as well as in industry at Pfizer and Boehringer Ingelheim. There, he led Global Business Development and Licensing for Cardiometabolic Diseases from 2007– 2019 resulting in a series of pre-clinical and clinical partnering transactions contributing to BI’s current pipeline and product portfolio. In addition, he acts as an adjunct Professor of Physiology at the University of Ulm, Germany. Johannes was trained in Animal Sciences and Biology at the University of Hohenheim in Germany, and held academic positions at the Medical Faculties of the Universities of Freiburg and Heidelberg until 1998.

Mrs Chahra Louafi

Chahra is the Investment Director and head of the fund for biotherapies and rare diseases at Bpifrance which she joined in 2001. She is also Vice-president of the Supervisory Board of Inserm Transfert Initiative and a member of the Supervisory Board of Cap Decisif Management. Previously she was in charge of project development and company inceptions in a private incubator for biotechnology companies. Chahra Louafi also sits on the Board of DBV Technologies, Sensorion, MedDay, Pixium Vision and Lysogene.

Mrs Catherine Boule

Catherine is a Partner at Cap Decisif, a Paris-based seed Fund, which she joined in 2003. She is also a Board Director at Axess Vision Technology, EyeBrain, Innavirvax, Eviagenics, Physikron, VitamFero, Laboratoire Watchfrog and Voluntis.

Mr. Ohad Hammer

Ohad has been a biotech analyst at Pontifax for 8 years. He is involved in identifying as well as evaluating new investment opportunities. Ohad focuses on early-stage projects and oversees scouting, due diligence and company formation. He also supports development and business development activities within Pontifax’s early-stage portfolio companies. Ohad obtained his M.S. in Biology from Tel-Aviv University and writes about small and mid-cap biotech stocks on his blog:

Mr. Fran├žois Thomas

François is Venture Partner at Sofimac Innovation, Paris. A medical oncologist by training, he has spent his career in exective management with big pharma and biotech in R&D , business development and executive management. He is a former partner at Atlas Ventures in London. In addition to Eyevensys, Dr. Thomas serves on a number of other boards, including Aelis Pharma, Biomodex, Inotrem, Sensorion and Step Pharma. 

Dominik Escher, Ph.D.

Dominik Escher is a founding partner of Pureos Bioventures. He is also president of the Swiss Biotech Association and a co-founder and Executive Chairman of CDR-Life. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to clinical proof-of-concept, delivering multiple clinically successful products (e.g. Beovu). Dominik obtained his Ph.D. in Molecular Biology from the University of Zurich and also holds a Masters Degree in Education with specialization in Management and Organization from the ETH of Zurich.

Neena Kadaba, Ph.D., GHS Fund

Neena is Director of Science at Quark Venture, which she joined in 2017. Previously, Neena was the director of strategic partnerships at QB3 at the California Institute for Quantitative Biosciences. There she created the QB3 Collaborative Startups program where she managed QB3’s multiyear, multimillion-dollar alliances with Calico and Pfizer and ran its precommercial $1 million annual grant program. She was also a partner at QB3’s venture fund, Mission Bay Capital. Previously, Neena was an associate and Kaufman Fellow at the Japanese trading company, Itochu Technology, Inc. Neena has been awarded the national P.E.O. Scholar Award, a Moore-Hufstedler Project Award, a DOW Career award, and a Ruth L. Kirschstein National Research Service Award. She earned her undergraduate and master’s degrees from the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts and her PhD in chemistry from the California Institute of Technology (CalTech), in Pasadena, California. She currently serves on MIT’s Educational Council.